

Accepted Manuscript

Title: Does switching to a second-generation tyrosine kinase inhibitor or increasing imatinib dose have long-term benefits in chronic myeloid leukemia patients with suboptimal responses under upfront standard-dose of imatinib?

Authors: Ahmet Emre Eskazan, Mario Tiribelli


PII: S0145-2126(18)30219-4
DOI: <https://doi.org/10.1016/j.leukres.2018.09.013>
Reference: LR 6045

To appear in: *Leukemia Research*

Received date: 16-7-2018

Please cite this article as: Eskazan AE, Tiribelli M, Does switching to a second-generation tyrosine kinase inhibitor or increasing imatinib dose have long-term benefits in chronic myeloid leukemia patients with suboptimal responses under upfront standard-dose of imatinib?, *Leukemia Research* (2018), <https://doi.org/10.1016/j.leukres.2018.09.013>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Does switching to a second-generation tyrosine kinase inhibitor or increasing imatinib dose have long-term benefits in chronic myeloid leukemia patients with suboptimal responses under upfront standard-dose of imatinib?

Ahmet Emre Eskazan¹, Mario Tiribelli²

¹Division of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey.

²Division of Hematology and BMT, Department of Medical Area, University of Udine, Udine, Italy.

***Corresponding Author:**

Ahmet Emre Eskazan
Istanbul University,
Cerrahpasa Faculty of Medicine,
Department of Internal Medicine,
Division of Hematology,
Fatih, Istanbul, Turkey
Tel: 90 533 722 73 76
Fax: 90 212 589 79 34
Email: emreeskazan@hotmail.com

Word count: 1,518

Reference count: 20

Key Words: chronic myeloid leukemia; dose escalation; imatinib; second-generation tyrosine kinase inhibitor; switch

Download English Version:

<https://daneshyari.com/en/article/11019519>

Download Persian Version:

<https://daneshyari.com/article/11019519>

[Daneshyari.com](https://daneshyari.com)